November 13, 2014
Researchers from the IDIBAPS and the University of Barcelona (UB) have described an interaction between the protein HNRNPA2B1 and pancreatic cancer development which remained unknown. The study, published in the journal Gastroenterology, has proved in human cancer cell lines that this protein is essential to the correct activity of the oncogenic protein KRAS, related to cancer start and development. The interaction between HNRNPA2B1 and the protein codified by the gene KRAS is a potential therapeutic target against pancreatic cancer, one of the tumours with a worse prognosis. The study was conducted by Neus Agell, professor at the Department of Cell Biology, Immunology and Neurosciences of the Faculty of Medicine of UB, who leads the Cellular compartments and signaling team at IDIBAPS. The first author of the study is Carles Barceló, PhD Student at the former UB Department.
November 12, 2014
A study shows that elite controllers have a similar genetic profile to that of HIV-uninfected people
The elite controllers (EC) are those people in whom AIDS does not progress despite being infected with HIV. A study led by the IDIBAPS and published in the PLOS ONE journal focuses on whether these EC have a specific genetic profile, different from other patients with HIV, which allows them to control viremia without the need of antiretroviral therapy. Thus, researchers have identified 23 miRNAs differentially expressed, four of which are over-expressed in EC and people without the disease and another 19 are under-expressed in this population compared to patients with HIV. The study was led by Dr. Mireia Arnedo and Dr. Montserrat Plana, researchers at the IDIBAPS group of Infectious Diseases and AIDS, led by Dr. Josep Maria Gatell. The article’s first author is Dr. Lander Egaña-Gorroño.
November 11, 2014
In a study published in New England Journal of Medicine (NEJM), a combination of oral antiviral obtained a 97% curation rate for hepatitis C in a group of liver transplant patients in which eradication of infection was only possible in less than 50% of cases until now. Dr. Xavier Forns, Head of Hepatitis Unit at Hospital Clínic and researcher at IDIBAPS and at the Networked Biomedical Research Center in Hepatic and Digestive Diseases (CIBEREHD), leads this study in which his group is the only European participant.
November 3, 2014
The TV3 Telethon Foundation celebrated yesterday evening a ceremony to present the projects selected to be funded by the 2013 edition dedicated to neurodegenerative diseases. The more than 11 million euro collected in the last edition have been distributed in 44 research projects, which have passed a rigorous evaluation process. Eleven of the chosen projects correspond to researchers from IDIBAPS, and therefore it becomes the institution that coordinates the greater number of projects in this edition.
October 31, 2014
The Institute of Biomedical Research August Pi i Sunyer (IDIBAPS) held on 23 and 24 October the first training course of the AstraZeneca Chair in Diabetes Innovation entitled "Innovation and diabetes: new strategies for implementation of research into clinical practice". It was addressed to specialists and primary care physicians, and its main objective was to convey the interest and research value to understand, prevent and cure diabetes and its complications. Another aspect discussed in this course was innovation in communication to achieve a change in patient's attitude towards the disease. This course was led by Dr. Ramon Gomis, Director of IDIBAPS, and Dr. Daniel Figuerola, from the Rossend Carrasco and Formiguera Foundation has collaborated together with other clinical experts and researchers in the field of type 2 diabetes from IDIBAPS and Hospital Clinic.